Which laboratory tests should be monitored in a patient on lithium therapy?

Laboratory Monitoring for Lithium Therapy

Patients on lithium require baseline and ongoing monitoring of serum lithium levels, renal function (creatinine/BUN), thyroid function (TSH), complete blood count, urinalysis, and serum calcium, with follow-up testing every 3-6 months during maintenance therapy 1, 2.

Baseline Laboratory Assessment

Before initiating lithium, obtain the following 1:

• Complete blood cell count
• Thyroid function tests (TSH)
• Renal function: Blood urea nitrogen (BUN), creatinine, and urinalysis
• Serum calcium
• Pregnancy test in females of childbearing age

The FDA label emphasizes baseline assessment of renal concentrating ability through routine urinalysis and tests evaluating tubular function (urine specific gravity or osmolality after water deprivation, or 24-hour urine volume) and glomerular function (serum creatinine or creatinine clearance) 2.

Acute Phase Monitoring

During acute treatment stabilization 2:

• Serum lithium levels: Check twice weekly until therapeutic level (1.0-1.5 mEq/L for acute mania) and clinical stability are achieved
• Draw blood samples 8-12 hours after the previous dose when concentrations are relatively stable

Maintenance Phase Monitoring

Once stable on maintenance therapy (target level 0.6-1.2 mEq/L) 1, 2:

• Serum lithium levels: Every 3-6 months (or at minimum every 2 months in uncomplicated cases)
• Renal function (creatinine, BUN): Every 3-6 months
• Thyroid function (TSH): Every 3-6 months
• Urinalysis: Every 3-6 months

Recent evidence from 2023 supports the 6-monthly testing interval, showing that most thyroid dysfunction manifests within 3 years of starting lithium, and that 3-monthly testing (the most common interval in practice) represents excessive frequency 3. A 2018 UK study found that only 76.2% of patients had lithium levels monitored at the recommended 6-month frequency, with even lower rates for thyroid (60.2%) and renal (72.7%) monitoring 4.

Special Considerations for Renal Monitoring

The FDA warns that chronic lithium therapy may cause diminished renal concentrating ability, nephrogenic diabetes insipidus with polyuria and polydipsia, and morphologic changes with glomerular and interstitial fibrosis 2. Progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment 2.

For older patients, recent 2025 guidelines recommend 5:

• More frequent monitoring: Every 8-10 weeks in elderly patients
• Target lower therapeutic levels: 0.4-0.6 mmol/L in older patients with good response
• Nephrology consultation if GFR falls below 30 mL/min/1.73 m²
• Do not initiate lithium if GFR is below 45 mL/min/1.73 m²

Critical Pitfalls to Avoid

1. Timing of blood draws matters: Always draw lithium levels 8-12 hours post-dose for accurate interpretation 2

2. Don't rely solely on serum levels: The FDA explicitly states "Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis" 2

3. Monitor for dehydration: Patients with polyuria/polydipsia must be carefully managed to avoid dehydration with resulting lithium retention and toxicity 2

4. Educate patients about symptoms: Periodic monitoring does not ensure abnormalities will be readily identified; patients and families must know presenting symptoms of potential adverse effects 1

5. Watch for drug interactions: NSAIDs, diuretics, and ACE inhibitors can reduce renal lithium clearance and precipitate toxicity 6

6. Elderly patients are more sensitive: They often respond to reduced dosages and may exhibit toxicity at serum levels ordinarily tolerated by others 2